Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 152

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 152
---
 following graph, the amount of compensation actually paid to our NEOs is not necessarily aligned with our net loss for each of the two fiscal years presented in the table. 96 DIRECTOR COMPENSATION The general policy of the Board is that compensation for independent directors should be a fair mix between cash and equity-based compensation. Additionally, the Company reimburses directors for reasonable expenses incurred during the course of their performance. There are no long-term incentive or medical reimbursement plans. The Company does not pay directors who are part of management for Board service in addition to their regular employee compensation. The Board determines the amount of director compensation. The Board may delegate such authority to the compensation committee. The following table sets forth the total cash and equity compensation paid to our non-employee directors for service on our board of directors during 2024:

| Name                         |     | Fees earned or 
 paid in cash   
 ($)            |        |     | Option-based 
 awards       
 ($)          |   |     | Total 
 ($)   |        |
| George Tidmarsh, M.D., Ph.D. |     |                | 60,000 |     |              | — |     |       | 60,000 |
| Jennifer Carver, BSN, MBA    |     |                | 60,000 |     |              | — |     |       | 60,000 |
| Jess Roper                   |     |                | 60,000 |     |              | — |     |       | 60,000 |
| Lakhmir Chawla, M.D.         |     |                | 60,000 |     |              | — |     |       | 60,000 |

97 DESCRIPTION OF SECURITIES Authorized and Outstanding Stock The Charter authorizes the issuance of an aggregate of 505,000,000 shares of capital stock, consisting of 500,000,000 Shares of Common Stock, $0.001 par value per share and 5,000,000 shares of preferred stock, $0.001 par value per share. The outstanding Shares of Common Stock are duly authorized, validly issued, fully paid and non-assessable. Our purpose is to engage in any lawful act or activity for which corporations may be organized under the DGCL. Unless our board of directors determines otherwise, we will issue all shares of our capital stock in uncertificated form. As of the date of this Prospectus, there were 963,796 Shares of Common Stock outstanding. We have 20,906,